18
total announcements
STAR.NS · 15 min delayed
Strides Pharma Science Limited
Strides Pharma Science Limited has received the Establishment Inspection Report (EIR) from the USFDA for its flagship facility in Bengaluru, indicating successful closure of the inspection.
Strides Pharma Science Limited
Strides Pharma Science Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on August 14, 2026. Further, the company has informed the Exchange regarding voting results.
Strides Pharma Science Limited
Strides Pharma Science Limited held its 35th Annual General Meeting on August 14, 2026, through video conference. The meeting was attended by the company's directors, officials, and representatives of statutory auditors, internal auditors, and secretarial auditors. The meeting was chaired by Mr. Arun Kumar, and the company's performance for the financial year ended March 31, 2026, was presented by Mr. Badree Komandur, Managing Director and Group CEO. Shareholders were given an opportunity to express their views and raise queries, which were suitably responded to by Mr. Badree Komandur. The AGM Notice, Board's Report, and Auditor's Report were taken as read, and the requisite statutory registers and other documents were available for electronic inspection.
Strides Pharma Science Limited
Strides Pharma Science Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a 13% year-on-year growth in topline, driven by broad-based contributions across its business, and maintained EBITDA margins at 18.2% despite external pressures.
Strides Pharma Science Limited
Strides Pharma Science Limited has informed the Exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Strides Pharma Science Limited
Strides Pharma Science Limited has made available the audio recording of its earnings call for Q1 FY27, which was held on July 31, 2026, to discuss unaudited financial results for the quarter ended June 30, 2026.
Strides Pharma Science Limited
Strides Pharma Science Limited has announced its Q1 FY 2027 earnings, with revenue growing 13% YoY to ₹12,654m, and EBITDA growing 5.4% YoY to ₹2,298m. The company has also divested its majority stake in Pivot Path, a captive GCC, and unlocked ₹1,000m of value. The company has improved its EcoVadis sustainability score to 68/100, a 19-point increase over last year.
Strides Pharma Science Limited
Strides Pharma Science Limited has announced its consolidated financial results for the quarter (Q1FY27) ended 30 June, 2026, with revenue at ₹12,654m, growing 13% YoY, and EBITDA at ₹2,298m, growing 5.4% YoY.
Strides Pharma Science Limited
Strides Pharma Science Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, to the National Stock Exchange of India and the Bombay Stock Exchange. The results were approved by the Board of Directors at their meeting held on July 31, 2026. The financial results are available on the company's website at www.strides.com.
Strides Pharma Science Limited
Strides Pharma Science Limited has scheduled an Earnings Call to discuss its Unaudited Financial Results for the quarter ended June 30, 2026.
Strides Pharma Science Limited
Strides Pharma Science Limited has submitted its Business Responsibility and Sustainability Report for FY 2026, as per SEBI regulations.
Strides Pharma Science Limited
Strides Pharma Science Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 14, 2026. The meeting will be held through Video Conference/ Other Audio-Visual Means (VC/ OAVM) and will consider the Audited Financial Statements for FY2025-26.
Strides Pharma Science Limited
Strides Pharma Science Limited has announced the record date for its final dividend as July 31, 2026, and has scheduled its 35th Annual General Meeting for August 14, 2026.
Strides Pharma Science Limited
Strides Pharma Science Limited has informed the Exchange about Certificate in terms of regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, enclosing certificates received from KFin Technologies Limited for the quarter ended June 30, 2026.
Strides Pharma Science Limited
Strides Pharma Science Limited has completed the sale of its majority stake in Pivot Path to a consortium led by Ascent Capital for ₹1,000 million, with ₹750 million received and the balance of ₹250 million payable on the first anniversary of the closing date.
Strides Pharma Science Limited
Strides Pharma Science Limited has partnered with Ascent Capital to sell a majority stake in its wholly-owned subsidiary, Pivot Path Private Limited, for an aggregate consideration of ~Rs. 1,000 million. Ascent Capital will also infuse ~Rs. 500 million into Pivot Path to accelerate its growth.
Strides Pharma Science Limited
Strides Pharma Science Limited has partnered with Ascent Capital to unlock value in Pivot Path, a wholly owned subsidiary, through a strategic investment. The transaction values Pivot Path at ₹2,300m post-money, enables Strides to realise ₹1,000m while retaining a 20% stake, and includes a primary capital infusion of ₹500 million to accelerate growth.
Strides Pharma Science Limited
Strides Pharma Science Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in shares of the Company shall remain closed from July 1, 2026, until 48 hours after declaration of the financial results of the Company for the quarter ended June 30, 2026.